KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF

No abstract is available for this paper.

• Publication year

  2002

• Venue

  HYPERTENSION

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.HYP.0000018588.56950.7APMID 12052848
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placenta Growth Factor

  2001cited by this paper
• Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats.

  2001cited by this paper
• Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.

  2001cited by this paper
• Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)

  2001cited by this paper
• Receptor-selective Variants of Human Vascular Endothelial Growth Factor

  2000cited by this paper
• Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1.

  1999cited by this paper
• Role of vascular endothelial growth factor in the regulation of angiogenesis.

  1999cited by this paper
• Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis

  1999cited by this paper
• A novel vascular endothelial growth factor encoded by Orf virus, VEGF‐E, mediates angiogenesis via signalling through VEGFR‐2 (KDR) but not VEGFR‐1 (Flt‐1) receptor tyrosine kinases

  1999cited by this paper
• Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.

  1999cited by this paper
• Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src*

  1999cited by this paper
• Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1

  1998cited by this paper
• Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection.

  1998cited by this paper
• A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain*

  1998cited by this paper
• Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.

  1997cited by this paper
• Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

  1997cited by this paper
• Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response.

  1997cited by this paper
• Vascular endothelial growth factor administration in chronic myocardial ischemia.

  1996cited by this paper
• VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts.

  1996cited by this paper
• Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.

  1996cited by this paper
• Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.

  1996cited by this paper
• The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation.

  1996cited by this paper
• Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis

  1995cited by this paper
• Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

  1995cited by this paper
• Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

  1995cited by this paper
• Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs.

  1994cited by this paper
• Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.

  1994cited by this paper
• Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.

  1994cited by this paper
• Enhanced Revascularization of the Ischemic Limb by Angiogenic Therapy

  1993cited by this paper
• Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries.

  1993cited by this paper
• Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.

  1991cited by this paper
• Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor

  1991cited by this paper
• Vascular endothelial growth factor is a secreted angiogenic mitogen.

  1989cited by this paper

• Patient-derived lung organoids from bronchoalveolar lavage capture epithelial heterogeneity and disease biology in bronchopulmonary dysplasia

  2026cites this paper
• Hot-water immersion: a (not so) new therapy for the primary and secondary prevention of hypertension?

  2025cites this paper
• Patient-derived airway organoids from BAL fluid model injury and therapy responses in neonatal bronchopulmonary dysplasia

  2025cites this paper
• Mapping the transcriptional architecture of glioblastoma at the single-cell level: Decoding heterogeneity, angiogenesis, and mesenchymal shifts

  2025cites this paper
• Study on the hypotensive effect and mechanism of hawthorn (Crataegus pinnatifida) fruits and hyperoside in spontaneously hypertensive rats.

  2024cites this paper
• An organotypic atlas of human vascular cells

  2024cites this paper
• Transcriptional Profiling of Human Endothelial Cells Unveils PIEZO1 and Mechanosensitive Gene Regulation by Prooxidant and Inflammatory Inputs

  2023cites this paper
• Design and synthesis of selective FLT3 inhibitors via exploration of back pocket II.

  2023cites this paper
• Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.

  2021cites this paper
• Angiogenic factors measured in aspirated placental tissue between the 10 + 6 and 18 + 3 weeks of gestation.

  2021cites this paper
• Anlotinib-Induced Hypertension: Current Concepts and Future Prospects.

  2021cites this paper
• Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia

  2020cites this paper
• B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine

  2020cites this paper
• Preeclampsia: Maternal Systemic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors

  2019cites this paper
• Capsaicinoids: Multiple effects on angiogenesis, invasion and metastasis in human cancers.

  2019cites this paper
• Decidual vascularization during organogenesis after perigestational alcohol ingestion.

  2019cites this paper
• RENAL INJURY IN PREECLAMPSIA: THE VIEW OF NEPHROLOGIST (LITERATURE REVIEW)

  2018cites this paper
• Exercise pattern and distance differentially affect hippocampal and cerebellar expression of FLK‐1 and FLT‐1 receptors in astrocytes and blood vessels

  2018cites this paper
• In Vitro Human Placental Studies to Support Adenovirus-Mediated VEGF-DΔNΔC Maternal Gene Therapy for the Treatment of Severe Early-Onset Fetal Growth Restriction

  2017cites this paper
• Bevacizumab‐induced hypertension: Clinical presentation and molecular understanding

  2017cites this paper
• Associations between urinary biomarkers of oxidative stress and air pollutants observed in a randomized crossover exposure to steel mill emissions.

  2017cites this paper
• An Overview on Current Issues and Challenges of Endothelial Progenitor Cell-Based Neovascularization in Patients with Diabetic Foot Ulcer

  2017cites this paper
• VEGF, the underlying factor for metabolic syndrome; fact or fiction?

  2017cites this paper
• In Situ Forming Gelatin Hydrogels-Directed Angiogenic Differentiation and Activity of Patient-Derived Human Mesenchymal Stem Cells

  2017cites this paper
• [Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

  2016cites this paper
• The expression and regulation of adrenomedullin in the human endometrium

  2016cites this paper
• Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis

  2016cites this paper
• Resistance to Angiokinase Inhibitors

  2016cites this paper
• Immunohistochemistry on rodent circulatory system: Its possible use in investigating hypertension

  2016cites this paper
• Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie

  2016cites this paper
• Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie

  2016cites this paper
• Maternal Therapy with Ad.VEGF-A165 Increases Fetal Weight at Term in a Guinea-Pig Model of Fetal Growth Restriction

  2016cites this paper
• with Ad.VEGF-A 165 increases fetal weight at term in a guinea pig model of restriction

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors

  2016cites this paper
• The Association between VEGFR Gene Polymorphisms and Stroke: A Meta-Analysis

  2016cites this paper
• Vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and genistein‐induced changes in the vascular reactivity of rat's aorta

  2015cites this paper
• Chronic and non-healing wounds: The story of vascular endothelial growth factor.

  2015cites this paper
• In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib

  2015influential citation
• VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress.

  2015cites this paper
• VEGF-induced blood flow increase causes vascular hyper-permeability in vivo.

  2015cites this paper
• Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)

  2015cites this paper
• A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy

  2015cites this paper
• Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot

  2014cites this paper
• Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

  2014cites this paper
• Leukocyte driven-decidual angiogenesis in early pregnancy

  2014cites this paper
• Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress

  2014influential citation
• Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

  2014cites this paper
• Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study

  2013cites this paper
• Bayesian Methods for Pharmacokinetic/Pharmacodynamic Modeling of Pazopanib‐Induced Increases in Blood Pressure and Transaminases

  2013cites this paper
• Tyrosine Phosphorylation Modulates the Vascular Responses of Mesenteric Arteries from Human Colorectal Tumors

  2013cites this paper
• Cardiovascular safety and hemodynamic considerations in oncology drug development – webinar highlights October 10th 2012

  2013cites this paper
• Immune cells control skin lymphatic electrolyte homeostasis and blood pressure.

  2013cites this paper
• abnormalities but not tumors Chuvash polycythemia VHL mutation with thrombosis and vascular Congenital disorder of oxygen sensing: association of the homozygous

  2013cites this paper
• VEGF Inhibition, Hypertension, and Renal Toxicity

  2012cites this paper
• Usefulness of Bevacizumab with the Treatment of Metastatic Colorectal Cancer

  2012cites this paper
• Vasorelaxation effect and mechanism of action of vascular endothelial growth factor-165 in isolated perfused human skin flaps.

  2012cites this paper
• Association between kinase insert domain-containing receptor gene polymorphisms and silent brain infarction: a Korean study.

  2012cites this paper
• Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension

  2012cites this paper
• Physiology and Pathophysiology of Wound Healing in Diabetes

  2012cites this paper
• Early Response to Anti-Tumoral Treatment in Hepatocellular Carcinoma – Can Quantitative Contrast-Enhanced Ultrasound Predict Outcome?

  2012cites this paper
• Inflammatory and Angiogenic Abnormalities in Diabetic Wound Healing: Role of Neuropeptides and Therapeutic Perspectives

  2012cites this paper
• Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.

  2012cites this paper
• Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer

  2012cites this paper
• Expression of angiogenic factors in placenta of stressed rats.

  2012cites this paper
• Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo*

  2011cites this paper
• VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications

  2011cites this paper
• Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate.

  2011cites this paper
• The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.

  2011cites this paper
• Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure?

  2011cites this paper
• Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence

  2011cites this paper
• Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

  2011cites this paper
• Regulation of endometrial repair and its impact on heavy menstrual bleeding

  2011cites this paper
• An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.

  2011cites this paper
• Selective stimulation of VEGFR2 accelerates progressive renal disease.

  2011cites this paper
• Cardiovascular, renal and thyroid toxicity during angiogenesis inhibition: A translational approach

  2011cites this paper
• Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

  2011cites this paper
• The Expression and Regulation of Adrenomedullin in the Human Endometrium: A Candidate for Endometrial Repair

  2011cites this paper
• Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion

  2010cites this paper
• Feasibility and tolerability of bevacizumab in children with primary CNS tumors

  2010cites this paper
• Inflammatory and Angiogenic Abnormalities in Diabetic Wound Healing: Role of Neuropeptides and Therapeutic Perspectives~!2009-09-05~!2009-09-20~!2010-03-04~!

  2010cites this paper
• Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension

  2010cites this paper
• Renal Involvement in Preeclampsia: Similarities to VEGF Ablation Therapy

  2010cites this paper
• Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function.

  2009cites this paper
• The role of the VirB/VirD4/Bep system in "Bartonella henselae"-triggered vascular proliferation

  2009cites this paper
• The Role of the VirB/VirD4/Bep System in Bartonella henselae-triggered Vascular Proliferation

  2009cites this paper
• 15-Lipoxygenase-1 in Atherosclerosis, Angiogenesis and Tumorigenesis

  2009cites this paper
• Local tissue distribution and cellular fate of vascular endothelial growth factor (VEGF) following intramuscular injection

  2009cites this paper
• Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

  2009cites this paper
• Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice

  2009cites this paper
• Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

  2009cites this paper
• Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor.

  2009cites this paper
• Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

  2009cites this paper
• VEGF kinase inhibitors: how do they cause hypertension?

  2009cites this paper
• Mode of action and clinical impact of VEGF signaling inhibitors

  2009cites this paper
• Current thoughts on angiogenesis.

  2009cites this paper
• Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects

  2009cites this paper
• Fisiopatologia de la cèl·lula endotelial en la cirrosi hepàtica

  2008cites this paper
• Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep

  2008cites this paper
• The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.

  2008cites this paper
• Evaluation Of VEGF Peptide Mimics As Inhibitors Of Angiogenesis

  2008cites this paper